{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/coronavirus-covid-19/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field bb7f5ed9-4196-4c4f-ab23-ab8700c423a1 --><h2>When should I suspect coronavirus infection?</h2><!-- end field bb7f5ed9-4196-4c4f-ab23-ab8700c423a1 -->","summary":"","htmlStringContent":"<!-- begin item d6f42d4a-6306-48b1-b6f0-ab8700c423a1 --><!-- begin field 74b534e4-4b75-407c-9153-ab8700c423a1 --><ul><li>COVID-19 has a predilection for the upper and lower respiratory tract alveolar cells and is spread by droplets from sneezing and coughing.</li><li>The prodrome (pre-illness phase) lasts between 2–10 days. </li><li>The commonest symptoms are fever, a new and continuous cough, shortness of breath, fatigue, loss of appetite, anosmia (loss of smell) and ageusia (loss of taste).</li><li>Other symptoms include headache, muscle pain, sore throat, nasal congestion, chest pain, nausea and vomiting, diarrhoea, skin rashes (especially in younger people). <ul><li>Delirium and reduced mobility can appear in the elderly and immunocompromised people, often in the absence of fever.</li></ul></li><li>A study in Spain reported the following patterns of skin rashes:<ul><li>Maculopapular eruptions (47%).</li><li>Acral areas of erythema with vesicles or pustules (so called ‘pseudo‐chilblains’) (19%) – this frequently appears later in the disease (59% after other symptoms). </li><li>Urticarial lesions (19%).</li><li>Other vesicular eruptions (9%) — vesicular eruptions appear early in the course of the disease (15% before other symptoms). <!--EndFragment--></li><li>Livedo or necrosis (6%). <!--EndFragment--></li></ul></li><li>The illness is variable in severity from asymptomatic, to mild upper respiratory tract infection in some people to severe pneumonia in others. </li></ul><!-- end field 74b534e4-4b75-407c-9153-ab8700c423a1 --><!-- end item d6f42d4a-6306-48b1-b6f0-ab8700c423a1 -->","topic":{"id":"6984fb85-3c40-5450-bda6-7957f9a560d7","topicId":"b76b302e-7ac5-44a1-aad7-ab8700c41ab2","topicName":"Coronavirus - COVID 19","slug":"coronavirus-covid-19","lastRevised":"Last revised in February 2021","chapters":[{"id":"d212a92c-0add-595b-a7d6-5a32867fe5f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d145562-2683-52db-accf-a80bedd6bb5e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes"},{"id":"f026a20a-e43c-59e7-883d-f0d7a1dbdd1a","slug":"update","fullItemName":"Update"}]},{"id":"bfc8a3e9-5b8f-5b1f-9059-3f9b1843015d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1d7208d4-4be1-5109-a3fc-f5fc9070f775","slug":"goals","fullItemName":"Goals"},{"id":"b64f49e4-a62d-56cd-abcb-f82c407e52e7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"51ea8ac4-fd38-524d-8566-e42974bfa9c4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"216d80a9-a8e3-5739-b592-c2d9ddd176ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cde80e77-2bd9-5594-9200-fe3a6fef7fc3","slug":"qipp","fullItemName":"QIPP"},{"id":"a24c3e94-065a-5767-9d41-cb69868045fc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a15744df-f80f-5b08-8993-b289c88d56a1","slug":"definition","fullItemName":"Definition"},{"id":"814f7a41-46c7-5e8c-9763-f02d81a30777","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e0a5f4e3-6adc-56a8-a13a-460ca5f3c39a","slug":"complications","fullItemName":"Complications"},{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response"},{"id":"11cbcb38-8a55-5f6a-8077-321789f26356","slug":"comparison-to-other-infections","fullItemName":"Comparison to Other Infections"},{"id":"448d1049-b54d-50a4-8a5e-aac889069c6f","slug":"disease-progression","fullItemName":"Disease Progression"}]},{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c0ddcd5-473d-5a66-8ae2-7fa97ad2e887","slug":"suspected-coronavirus-infection","fullItemName":"Scenario: Suspected coronavirus infection"},{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization"},{"id":"e148d0d4-0f10-53c6-94bf-27e92c5eb531","slug":"management-of-other-medical-conditions","fullItemName":"Scenario: Management of other medical conditions"},{"id":"18839f74-7d09-5801-9fc9-1ca496cccf09","slug":"palliative-care","fullItemName":"Scenario: Palliative care"},{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues"},{"id":"f6aa749f-0a06-5ca2-b3cd-e01327e4ef76","slug":"managing-long-term-effects","fullItemName":"Scenario: Managing long-term effects"},{"id":"8d7143f7-6842-52e2-8644-5060222c472f","slug":"clinical-resources","fullItemName":"Scenario: Clinical resources"}]},{"id":"ee648ec4-3617-53c8-b0d5-ade1caeb5cfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ea7d7ae-64e1-581e-856d-9daa5d3570ba","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d29ccf56-f68d-5ce0-b726-09ba9ed827e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84321e07-ed6b-5815-b7a9-de40ab2acde2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfaeb9ab-79ce-5851-a900-fdd0ab56f8fd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73f8f10-2617-514f-b07d-8f52fb8e7f2f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"586fa044-aa51-5fdc-895a-922bedd17946","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"66b3f0cb-7cb5-5f38-8632-30b8411234e4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"bff65eea-6af2-5bcc-ae6c-8325a0d55ee1","slug":"basis-for-recommendation-700","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field a3a773ad-0674-4ebd-bda0-ab8700c423a1 --><h3>Basis for recommendation</h3><!-- end field a3a773ad-0674-4ebd-bda0-ab8700c423a1 -->","summary":null,"htmlStringContent":"<!-- begin item 700b9d12-8371-4ea2-9ffd-ab8700c423a1 --><!-- begin field e7e0984a-664d-45b4-8906-ab8700c423a1 --><p>This information is based on the Public Health England (PHE) document <em>COVID-19: epidemiology, virology and clinical features</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020c</a>], a report of 72, 314 case series [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Wu and McGoogan, 2020</a>], a retrospective study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Chen et al, 2020</a>], and a prospective consensus study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Galv&aacute;n Casas, 2020</a>].</p><ul><li>In a study of the first 99 patients diagnosed with COVID-19 in China, it was found that the majority of people had fever or cough (83%) and a third of patients had shortness of breath. Other symptoms included muscle ache, headache, confusion, chest pain, and vomiting and diarrhoea (3% and 5%). Many patients presented with organ function damage, including 17 (17%) with acute respiratory distress syndrome (ARDS), eight (8%) with acute respiratory injury, three (3%) with acute kidney injury, four (4%) with sepsis, and one (1%) with ventilator-associated pneumonia. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Wu and McGoogan, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Chen et al, 2020</a>]</p><ul><li><!--StartFragment--><div>A study in Spain of 375 people with COVID-19 reported the following patterns of cutaneous manifestations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">Galv&aacute;n Casas, 2020</a>]:</div><ul><li><div>Maculopapular eruptions (47%).</div></li><li><div>Acral areas of erythema with vesicles or pustules (so called ‘pseudo‐chilblains’) (19%).</div></li><li><div>Urticarial lesions (19%).</div></li><li><div>Other vesicular eruptions (9%).</div></li><li><div>Livedo or necrosis (6%).</div></li></ul></li><li>The authors noted that vesicular eruptions appear early in the course of the disease (15% before other symptoms) and the ‘pseudo‐chilblain’ pattern frequently appears later in the disease (59% after other symptoms), while the rest tend to appear with the other symptoms of COVID‐19.  <br><!--EndFragment--></li></ul><!-- end field e7e0984a-664d-45b4-8906-ab8700c423a1 --><!-- end item 700b9d12-8371-4ea2-9ffd-ab8700c423a1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}